{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:57:53Z","timestamp":1786543073747,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R15HD097588"],"award-info":[{"award-number":["R15HD097588"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40264-022-01267-z","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T03:03:01Z","timestamp":1673838181000},"page":"257-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study"],"prefix":"10.1007","volume":"46","author":[{"given":"Shuang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimford J.","family":"Meador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Pawasauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Lewkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina E.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd N.","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Hartzema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Quilliam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-7895","authenticated-orcid":false,"given":"Xuerong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"1","key":"1267_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0976-3147.91934","volume":"3","author":"PJ Whelan","year":"2012","unstructured":"Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45\u201350. https:\/\/doi.org\/10.4103\/0976-3147.91934.","journal-title":"J Neurosci Rural Pract."},{"issue":"3","key":"1267_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.semperi.2019.01.003","volume":"43","author":"CE Rodriguez","year":"2019","unstructured":"Rodriguez CE, Klie KA. Pharmacological treatment of opioid use disorder in pregnancy. Semin Perinatol. 2019;43(3):141\u20138. https:\/\/doi.org\/10.1053\/j.semperi.2019.01.003.","journal-title":"Semin Perinatol"},{"issue":"3","key":"1267_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jsat.2007.10.007","volume":"35","author":"HE Jones","year":"2008","unstructured":"Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35(3):245\u201359. https:\/\/doi.org\/10.1016\/j.jsat.2007.10.007.","journal-title":"J Subst Abuse Treat"},{"issue":"1\u20132","key":"1267_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","volume":"104","author":"JR Bell","year":"2009","unstructured":"Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104(1\u20132):73\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.03.020.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1267_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ntt.2010.09.003","volume":"33","author":"LM Jansson","year":"2011","unstructured":"Jansson LM, DiPietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol. 2011;33(2):240\u20133. https:\/\/doi.org\/10.1016\/j.ntt.2010.09.003.","journal-title":"Neurotoxicol Teratol"},{"issue":"S1","key":"1267_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1360-0443.2012.04037.x","volume":"107","author":"AL Salisbury","year":"2012","unstructured":"Salisbury AL, Coyle MG, O\u2019Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction. 2012;107(S1):36\u201344. https:\/\/doi.org\/10.1111\/j.1360-0443.2012.04037.x.","journal-title":"Addiction"},{"key":"1267_CR7","doi-asserted-by":"publisher","first-page":"S38887","DOI":"10.4137\/SART.S38887","volume":"10","author":"KE Wurst","year":"2016","unstructured":"Wurst KE, Zedler BK, Joyce AR, Sasinowski M, Murrelle EL. A Swedish population-based study of adverse birth outcomes among pregnant women treated with buprenorphine or methadone: preliminary findings. Subst Abuse. 2016;10:S38887. https:\/\/doi.org\/10.4137\/SART.S38887.","journal-title":"Subst Abuse"},{"issue":"2","key":"1267_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/ADM.0000000000000092\/","volume":"9","author":"MC Meyer","year":"2015","unstructured":"Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9(2):81\u20136. https:\/\/doi.org\/10.1097\/ADM.0000000000000092\/.","journal-title":"J Addict Med"},{"issue":"1","key":"1267_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.drugalcdep.2012.07.001","volume":"127","author":"GK Welle-Strand","year":"2013","unstructured":"Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127(1):200\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.07.001.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1267_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.drugalcdep.2008.01.025","volume":"96","author":"J Kakko","year":"2008","unstructured":"Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96(1):69\u201378. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.01.025.","journal-title":"Drug Alcohol Depend"},{"issue":"24","key":"1267_CR11","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","volume":"363","author":"HE Jones","year":"2010","unstructured":"Jones HE, Stine SM, O\u2019Grady KE, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","volume":"101","author":"G Fischer","year":"2006","unstructured":"Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275\u201381. https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01321.x.","journal-title":"Addiction"},{"issue":"10","key":"1267_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00228-011-1049-9","volume":"67","author":"I Lacroix","year":"2011","unstructured":"Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67(10):1053. https:\/\/doi.org\/10.1007\/s00228-011-1049-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1267_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1017\/S2040174412000190","volume":"3","author":"AL Gordon","year":"2012","unstructured":"Gordon AL, Lopatko OV, Haslam RR, et al. Ineffective morphine treatment regimen for the control of neonatal abstinence syndrome in buprenorphine- and methadone-exposed infants. J Dev Origin Health Dis. 2012;3(4):262\u201370. https:\/\/doi.org\/10.1017\/S2040174412000190.","journal-title":"J Dev Origin Health Dis"},{"issue":"8","key":"1267_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jama.2017.7818","volume":"318","author":"W Frazier","year":"2017","unstructured":"Frazier W, Cochran G, Lo-Ciganic WH, et al. Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid. JAMA. 2017;318(8):750\u20132. https:\/\/doi.org\/10.1001\/jama.2017.7818.","journal-title":"JAMA"},{"key":"1267_CR16","unstructured":"US Food and Drug Administration and others. Information about medication-assisted treatment (MAT). Published online April 18, 2019. https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medication-assisted-treatment-mat. Accessed 9 Oct 2022."},{"issue":"9","key":"1267_CR17","doi-asserted-by":"publisher","first-page":"e1003322","DOI":"10.1371\/journal.pmed.1003322","volume":"17","author":"E Patorno","year":"2020","unstructured":"Patorno E, Hernandez-Diaz S, Huybrechts KF, et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med. 2020;17(9):e1003322. https:\/\/doi.org\/10.1371\/journal.pmed.1003322.","journal-title":"PLoS Med"},{"issue":"4","key":"1267_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/10550887.2016.1177809","volume":"35","author":"C Zhang","year":"2016","unstructured":"Zhang C, Brook JS, Leukefeld CG, Brook DW. Associations between compulsive buying and substance dependence\/abuse, major depressive episodes, and generalized anxiety disorder among men and women. J Addict Dis. 2016;35(4):298\u2013304. https:\/\/doi.org\/10.1080\/10550887.2016.1177809.","journal-title":"J Addict Dis"},{"issue":"5","key":"1267_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/AOG.0000000000003231","volume":"133","author":"EE Krans","year":"2019","unstructured":"Krans EE, Kim JY, James AE, Kelley D, Jarlenski MP. Medication-assisted treatment utilization among pregnant women with opioid use disorder. Obstet Gynecol. 2019;133(5):943\u201351. https:\/\/doi.org\/10.1097\/AOG.0000000000003231.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"1267_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","volume":"132","author":"Z Schuman-Olivier","year":"2013","unstructured":"Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend. 2013;132(3):580\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.04.006.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1267_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/ADM.0b013e3182266a3a","volume":"5","author":"EM Wachman","year":"2011","unstructured":"Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med. 2011;5(4):293\u20139. https:\/\/doi.org\/10.1097\/ADM.0b013e3182266a3a.","journal-title":"J Addict Med"},{"key":"1267_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.drugpo.2018.02.001","volume":"55","author":"NZ Janjua","year":"2018","unstructured":"Janjua NZ, Islam N, Kuo M, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018;55:31\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2018.02.001.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1267_CR23","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1267_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/aje\/kwh131","volume":"159","author":"LM Bodnar","year":"2004","unstructured":"Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am J Epidemiol. 2004;159(10):926\u201334. https:\/\/doi.org\/10.1093\/aje\/kwh131.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1267_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/00952990.2017.1399403","volume":"44","author":"DC Chang","year":"2018","unstructured":"Chang DC, Klimas J, Wood E, Fairbairn N. Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions. Am J Drug Alcohol Abuse. 2018;44(2):143\u20136. https:\/\/doi.org\/10.1080\/00952990.2017.1399403.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"1267_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ Van der Weele","year":"2017","unstructured":"Van der Weele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med"},{"key":"1267_CR27","first-page":"253","volume":"70","author":"DR Gerstein","year":"1992","unstructured":"Gerstein DR. The effectiveness of drug treatment. Res Publ Assoc Res Nerv Ment Dis. 1992;70:253\u201382.","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"issue":"22","key":"1267_CR28","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","volume":"372","author":"VN Tolia","year":"2015","unstructured":"Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372(22):2118\u201326. https:\/\/doi.org\/10.1056\/NEJMsa1500439.","journal-title":"N Engl J Med"},{"issue":"18","key":"1267_CR29","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2012.3951","volume":"307","author":"SW Patrick","year":"2012","unstructured":"Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000\u20132009. JAMA. 2012;307(18):1934\u201340. https:\/\/doi.org\/10.1001\/jama.2012.3951.","journal-title":"JAMA"},{"issue":"10","key":"1267_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1542\/hpeds.2015-0024","volume":"5","author":"SW Patrick","year":"2015","unstructured":"Patrick SW, Burke JF, Biel TJ, Auger KA, Goyal NK, Cooper WO. Risk of hospital readmission among infants with neonatal abstinence syndrome. Hosp Pediatr. 2015;5(10):513\u20139. https:\/\/doi.org\/10.1542\/hpeds.2015-0024.","journal-title":"Hosp Pediatr"},{"issue":"5","key":"1267_CR31","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/AOG.0b013e318256496e","volume":"119","author":"ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine","year":"2012","unstructured":"ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070\u20136. https:\/\/doi.org\/10.1097\/AOG.0b013e318256496e.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1267_CR32","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1542\/peds.2011-3212","volume":"129","author":"ML Hudak","year":"2012","unstructured":"Hudak ML, Tan RC. Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540\u201360. https:\/\/doi.org\/10.1542\/peds.2011-3212.","journal-title":"Pediatrics"},{"issue":"4","key":"1267_CR33","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1542\/peds.2008-2888","volume":"123","author":"M O\u2019Donnell","year":"2009","unstructured":"O\u2019Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics. 2009;123(4):e614\u201321. https:\/\/doi.org\/10.1542\/peds.2008-2888.","journal-title":"Pediatrics"},{"issue":"1","key":"1267_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.11.013","volume":"79","author":"HE Jones","year":"2005","unstructured":"Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1\u201310. https:\/\/doi.org\/10.1016\/j.drugalcdep.2004.11.013.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1267_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/hup.1224","volume":"26","author":"V Metz","year":"2011","unstructured":"Metz V, Jagsch R, Ebner N, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol. 2011;26(6):412\u201321. https:\/\/doi.org\/10.1002\/hup.1224.","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"1267_CR36","doi-asserted-by":"publisher","first-page":"e205734","DOI":"10.1001\/jamanetworkopen.2020.5734","volume":"3","author":"DM Schiff","year":"2020","unstructured":"Schiff DM, Nielsen T, Hoeppner BB, et al. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. JAMA Netw Open. 2020;3(5):e205734. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5734.","journal-title":"JAMA Netw Open"},{"issue":"22","key":"1267_CR37","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136. https:\/\/doi.org\/10.1056\/NEJMp1402780.","journal-title":"N Engl J Med"},{"issue":"4","key":"1267_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1377\/hlthaff.2018.05075","volume":"38","author":"A Kennedy-Hendricks","year":"2019","unstructured":"Kennedy-Hendricks A, Levin J, Stone E, McGinty EE, Gollust SE, Barry CL. News media reporting on medication treatment for opioid use disorder amid the opioid epidemic. Health Aff. 2019;38(4):643\u201351. https:\/\/doi.org\/10.1377\/hlthaff.2018.05075.","journal-title":"Health Aff"},{"issue":"14","key":"1267_CR39","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/jama.2014.2147","volume":"311","author":"Y Olsen","year":"2014","unstructured":"Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder\u2014and its treatment. JAMA. 2014;311(14):1393\u20134. https:\/\/doi.org\/10.1001\/jama.2014.2147.","journal-title":"JAMA"},{"issue":"4","key":"1267_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jsat.2011.06.005","volume":"41","author":"J Gryczynski","year":"2011","unstructured":"Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011;41(4):431\u20139. https:\/\/doi.org\/10.1016\/j.jsat.2011.06.005.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"1267_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/ajad.13097","volume":"29","author":"A Jordan","year":"2020","unstructured":"Jordan A, Jegede O. Building outreach and diversity in the field of addictions: building outreach and diversity. Am J Addict. 2020;29(5):413\u20137. https:\/\/doi.org\/10.1111\/ajad.13097.","journal-title":"Am J Addict"},{"issue":"4","key":"1267_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475\u201386. https:\/\/doi.org\/10.1046\/j.1360-0443.1998.9344753.x.","journal-title":"Addiction"},{"key":"1267_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsat.2017.06.005","volume":"80","author":"CM Wilder","year":"2017","unstructured":"Wilder CM, Hosta D, Winhusen T. Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. J Subst Abuse Treat. 2017;80:33\u20136. https:\/\/doi.org\/10.1016\/j.jsat.2017.06.005.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"1267_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/AOG.0000000000000640","volume":"125","author":"SL Wiegand","year":"2015","unstructured":"Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015;125(2):363\u20138. https:\/\/doi.org\/10.1097\/AOG.0000000000000640.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"1267_CR45","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1515\/jpm-2020-0106","volume":"48","author":"CL Staszewski","year":"2020","unstructured":"Staszewski CL, Garretto D, Garry ET, Ly V, Davis JA, Herrera KM. Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies. J Perinatal Med. 2020;48(7):677\u201380. https:\/\/doi.org\/10.1515\/jpm-2020-0106.","journal-title":"J Perinatal Med."},{"key":"1267_CR46","doi-asserted-by":"publisher","unstructured":"Burke MA, Sullivan R. The Medicaid expansion and the uptake of medication-assisted treatment for opioid use disorder: evidence from the Rhode Island All-Payer Claims Database, 2012\u20132018. Published online 22 April, 2021. https:\/\/doi.org\/10.2139\/ssrn.3832241.","DOI":"10.2139\/ssrn.3832241"},{"key":"1267_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1257\/pandp.20191090","volume":"109","author":"J Grooms","year":"2019","unstructured":"Grooms J, Ortega A. Examining Medicaid expansion and the treatment of substance use disorders. AEA Papers Proc. 2019;109:187\u201391. https:\/\/doi.org\/10.1257\/pandp.20191090.","journal-title":"AEA Papers Proc"},{"issue":"5","key":"1267_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n M\u00c1, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360.","journal-title":"Epidemiology"},{"issue":"11","key":"1267_CR49","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/01.ogx.0000286562.31774.76","volume":"62","author":"AH Schempf","year":"2007","unstructured":"Schempf AH. Illicit drug use and neonatal outcomes: a critical review. Obstet Gynecol Surv. 2007;62(11):749\u201357. https:\/\/doi.org\/10.1097\/01.ogx.0000286562.31774.76.","journal-title":"Obstet Gynecol Surv"},{"issue":"9","key":"1267_CR50","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/j.1530-0277.2011.01513.x","volume":"35","author":"Y Meyer-Leu","year":"2011","unstructured":"Meyer-Leu Y, Lemola S, Daeppen JB, Deriaz O, Gerber S. Association of moderate alcohol use and binge drinking during pregnancy with neonatal health. Alcohol Clin Exp Res. 2011;35(9):1669\u201377. https:\/\/doi.org\/10.1111\/j.1530-0277.2011.01513.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1267_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2012.03.008","volume":"135","author":"F Oyebode","year":"2012","unstructured":"Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012;135(1):71\u20137. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.03.008.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1267_CR52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"M\u00c1 Hern\u00e1n","year":"2000","unstructured":"Hern\u00e1n M\u00c1, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561\u201370.","journal-title":"Epidemiology"},{"issue":"454","key":"1267_CR53","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1198\/016214501753168154","volume":"96","author":"MA Hern\u00e1n","year":"2001","unstructured":"Hern\u00e1n MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96(454):440\u20138. https:\/\/doi.org\/10.1198\/016214501753168154.","journal-title":"J Am Stat Assoc"},{"issue":"9313","key":"1267_CR54","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hern\u00e1n MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(02)08213-2.","journal-title":"Lancet"},{"issue":"11","key":"1267_CR55","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/aje\/155.11.1045","volume":"155","author":"NR Cook","year":"2002","unstructured":"Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians\u2019 Health Study. Am J Epidemiol. 2002;155(11):1045\u201353. https:\/\/doi.org\/10.1093\/aje\/155.11.1045.","journal-title":"Am J Epidemiol"},{"key":"1267_CR56","doi-asserted-by":"publisher","first-page":"h2102","DOI":"10.1136\/bmj.h2102","volume":"350","author":"RJ Desai","year":"2015","unstructured":"Desai RJ, Huybrechts KF, Hernandez-Diaz S, et al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ. 2015;350:h2102. https:\/\/doi.org\/10.1136\/bmj.h2102.","journal-title":"BMJ"},{"issue":"1","key":"1267_CR57","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/GRF.0b013e31827feea4","volume":"56","author":"BA Logan","year":"2013","unstructured":"Logan BA, Brown MS, Hayes MJ. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin Obstet Gynecol. 2013;56(1):186\u201392. https:\/\/doi.org\/10.1097\/GRF.0b013e31827feea4.","journal-title":"Clin Obstet Gynecol"},{"issue":"2","key":"1267_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/EDE.0000000000000780","volume":"29","author":"LS Lemon","year":"2018","unstructured":"Lemon LS, Caritis SN, Venkataramanan R, Platt RW, Bodnar LM. Methadone versus buprenorphine for opioid use dependence and risk of neonatal abstinence syndrome. Epidemiology. 2018;29(2):261\u20138. https:\/\/doi.org\/10.1097\/EDE.0000000000000780.","journal-title":"Epidemiology"},{"issue":"5","key":"1267_CR59","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","volume":"29","author":"MB Mathur","year":"2018","unstructured":"Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web site and R package for computing E-values. Epidemiology. 2018;29(5):e45. https:\/\/doi.org\/10.1097\/EDE.0000000000000864.","journal-title":"Epidemiology"},{"issue":"4","key":"1267_CR60","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/EDE.0000000000000658","volume":"28","author":"CV Ananth","year":"2017","unstructured":"Ananth CV, Friedman AM, Keyes KM, Lavery JA, Hamilton A, Wright JD. Primary and repeat cesarean deliveries: a population-based study in the United States, 1979\u20132010. Epidemiology. 2017;28(4):567\u201374. https:\/\/doi.org\/10.1097\/EDE.0000000000000658.","journal-title":"Epidemiology"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01267-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01267-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01267-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:25:26Z","timestamp":1678119926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01267-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01267-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"24 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number R15HD097588 (Principal Investigator: Dr. Xuerong Wen). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Abraham Hartzema is the CSO of Suremed Compliance LLC and received a business grant from the NIH\/NIDA (R44DA 051272-01, 08\/01\/2020\u201307\/31\/2023, total budget 1.6M). Kimford J. Meador has received research support from the National Institutes of Health and Sunovion Pharmaceuticals, and travel support from Eisai. The Epilepsy Study Consortium pays Kimford J. Meador\u2019s university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, and UCB Pharma. Jayne Pawasauskas is on the speakers\u2019 bureau for Heron Therapeutics. Adam K. Lewkowitz is supported by the NICHD (K23 HD103961-A1), and his research is also supported by Essential Hospitals Institute\/CVS Health Foundation and Pharmacosmos Therapeutics, Inc. Adam K. Lewkowitz was a paid speaker for Pharmacosmos as well. The other authors have no conflicts of interests that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved and granted a waiver of informed consents by the Institutional Review Board of The University of Rhode Island (IRB 1289357-4) and Rhode Island Department of Health (IRB#: 2019-11).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"We thank the Rhode Island Department of Health and the Executive Office of Health and Human Services for providing the data access. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the Rhode Island Department of Health upon appropriate application ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The codes used in this study are available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SW and XW have full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: XW, SW, KJM. Acquisition, analysis, or interpretation of data: SW, XW. Drafting of the manuscript: SW, XW, KJM. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: SW. Clinical, technical, or material support: JP, AKL, KEW, TNB, AH, BJQ. Supervision: Wen, KJM. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}